Trites Michael J, Li Lei, Njoku Uche, Akl May G, Hydomako Aidan, Widenmaier Scott B
Department of Anatomy, Physiology, and Pharmacology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Department of Anatomy, Physiology, and Pharmacology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Cell Mol Gastroenterol Hepatol. 2025 May 29;19(9):101550. doi: 10.1016/j.jcmgh.2025.101550.
BACKGROUND & AIMS: Sepsis and endotoxemia cause mortality by inducing organ dysfunction and damage. Liver defends against such insults by mediating metabolic adaptations that promote stress and damage control. The mechanisms underlying liver defenses may require coordinated actions between cellular and systemic stress-defense programming. Here, we investigated whether the stress-defending transcription factors nuclear factor erythroid 2 related factor-1 (Nrf1) and -2 (Nrf2) in hepatocytes protect against endotoxemia and sepsis.
We used mice injected with Escherichia coli-derived lipopolysaccharide (endotoxemia), or E coli (sepsis). Hepatic Nrf1 and Nrf2 activity was examined, and we also genetically altered their activity and examined corresponding effects on survival, body temperature, cytokines and liver inflammation, liver gene and protein expression, and liver-related metabolism.
Hepatic Nrf1 and Nrf2 activity was reduced in endotoxemia and sepsis, and deficiency for hepatic Nrf1, but not Nrf2, promoted severe hypothermia and mortality. Conversely, increasing hepatic Nrf1 activity mitigated hypothermia and improved survival. These effects were linked to very-low-density lipoprotein (VLDL) secretion and triglyceride metabolism. In endotoxemia, hepatic Nrf1 deficiency reduced VLDL secretion, whereas increased hepatic Nrf1 activity enhanced VLDL secretion. Administering a VLDL secretion inhibitor, lomitapide, or inhibitor of circulating triglyceride hydrolysis, poloxamer 407, diminished protective effects of hepatic Nrf1 activity, whereas administering intralipid rescued the lomitapide-injected mice. Gene expression profiling indicates Nrf1 promotes this effect by regulating stress-defense programming.
Mortality in endotoxemia and sepsis is exacerbated by impaired hepatic Nrf1 activity. Interventions increasing hepatic Nrf1 activity promote liver defenses that protect against sepsis-associated hypothermia and mortality.
脓毒症和内毒素血症通过诱导器官功能障碍和损伤导致死亡。肝脏通过介导促进应激和损伤控制的代谢适应来抵御此类损伤。肝脏防御的潜在机制可能需要细胞和全身应激防御程序之间的协同作用。在此,我们研究了肝细胞中应激防御转录因子核因子红系2相关因子-1(Nrf1)和-2(Nrf2)是否能抵御内毒素血症和脓毒症。
我们使用注射了大肠杆菌衍生脂多糖(内毒素血症)或大肠杆菌(脓毒症)的小鼠。检测肝脏Nrf1和Nrf2活性,我们还通过基因改变它们的活性,并检测对生存、体温、细胞因子和肝脏炎症、肝脏基因和蛋白质表达以及肝脏相关代谢的相应影响。
在内毒素血症和脓毒症中,肝脏Nrf1和Nrf2活性降低,肝脏Nrf1而非Nrf2的缺乏会促进严重体温过低和死亡。相反,增加肝脏Nrf1活性可减轻体温过低并提高生存率。这些作用与极低密度脂蛋白(VLDL)分泌和甘油三酯代谢有关。在内毒素血症中,肝脏Nrf1缺乏会减少VLDL分泌,而增加肝脏Nrf1活性会增强VLDL分泌。给予VLDL分泌抑制剂洛米他派或循环甘油三酯水解抑制剂泊洛沙姆407会减弱肝脏Nrf1活性的保护作用,而给予脂肪乳剂可挽救注射洛米他派的小鼠。基因表达谱分析表明Nrf1通过调节应激防御程序促进了这种作用。
肝脏Nrf1活性受损会加剧内毒素血症和脓毒症的死亡率。增加肝脏Nrf1活性的干预措施可促进肝脏防御,预防脓毒症相关的体温过低和死亡。